For the quarter ending 2026-03-31, BBIO made $194,515K in revenue. -$164,043K in net income. Net profit margin of -84.33%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues, net | 194,515 | 155,179* | 120,700 | 110,565 |
| Cost Of License Services And Royalty Revenue | - | - | - | 805 |
| Product | 7,732 | 7,968* | 4,028 | - |
| Cost Of Goods Sold | - | - | - | 2,848 |
| License Services And Royalty | 2,207 | -2,330* | 2,535 | - |
| Total cost of revenues | 9,939 | 5,638* | 6,563 | 3,653 |
| Research and development | 126,636 | 115,796* | 112,874 | 111,231 |
| Selling, general and administrative | 163,896 | 131,062* | 137,621 | 129,154 |
| Restructuring, impairment, and related charges | 0 | 6,878* | 8,841 | 805 |
| Total operating costs and expenses | 300,471 | 259,373* | 265,899 | 244,843 |
| Loss from operations | -105,956 | -104,194* | -145,199 | -134,278 |
| Interest income | 6,246 | 4,649* | 6,239 | 3,898 |
| Interest expense | 12,942 | -20,961* | 11,739 | 37,637 |
| Noncash interest expense on deferred royalty obligations | 39,873 | 15,908* | 36,410 | - |
| Gain on deconsolidation of subsidiaries | - | 0* | 0 | 0 |
| Loss on extinguishment of debt | 0 | -75,769* | 0 | 0 |
| Net loss from equity method investments | -18,283 | -18,573* | -15,834 | -20,189 |
| Other income, net | 4,253 | 8,545* | 16,461 | 6,548 |
| Total other expense, net | -60,599 | -76,097* | -41,283 | -47,380 |
| Loss before income taxes | - | -180,292* | -186,482 | -181,658 |
| Provision for income taxes | - | -397* | -1,545 | 2,100 |
| Net loss | -166,555 | -179,895* | -184,937 | -183,758 |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | -2,512 | -1,933* | -2,194 | -1,855 |
| Net loss attributable to common stockholders of bridgebio | -164,043 | -177,962 | -182,743 | -181,903 |
| Basic EPS | -0.84 | -0.926 | -0.95 | -0.95 |
| Diluted EPS | -0.84 | -0.926 | -0.95 | -0.95 |
| Basic Average Shares | 194,789,897 | 192,211,079 | 191,854,152 | 190,517,215 |
| Diluted Average Shares | 194,789,897 | 192,211,079 | 191,854,152 | 190,517,215 |
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)